Mucositis

Mucosal damages from chemotherapy in association in association with autologous, allogeneic transplantation and high dose chemotherapy is a significant problem for patients. The department has co-chaired a mucositis advisory group of the EBMT which includes members of the working parties for infectious diseases and chronic leukaemia. The working parties are currently carrying out a randomised prospective trial on the use of a new agent TKGF growth factor in the prevention of mucosal damage.

Drug development agents which may be of use in the treatment of chronic myeloid leukaemia and chronic lymphocytic leukaemia are currently being developed in the Department under the direction of Professor Mark Lawler.

Publications

The Prospective Oral Mucositis Audit: relationship of severe mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. McCann S, Schwenkglenks M, Bacon P, Einsele H, D'Addio A, Maertens J, Neiderwieser D, Rabitch W, Roosar A, Ruutu T, Schouten H, Stone R, Vorkurka S, Quinn B, Blijlevens N. Bone Marrow Transplantation. 2008. Sept

Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving Hogh-dose Melphalan or BEAM Conditioning Chemotherapy – European Blood and Marrow Transplantation Mucositis Advisory Group. N Blijlevens, M Schwengkglenks, P Bacon, A D'Addio, H Einsele, J Martens, D Niederwieser, W Rabitsch, A Roostaar, H Schouten, R Stone, S Vakurka, B Quinn and S McCann for EBMT. J Clin Oncol 26((9): 1519-1525. 2008.

Principle investigators

Back to list of Research Projects